GlassScriptPhysician profile
Tejinder C Kaur
NPI 1649210816
$14,596.91
in general payments reported to CMS, 2019-2025
67 companies · $2,562 in 2025
The $2,562 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,775 · 2020: $1,056 · 2021: $1,966 · 2022: $2,951 · 2023: $2,333 · 2024: $1,952 · 2025: $2,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,762 · Education: $85.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,761.99 |
| Education | $85.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,251.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,230.23 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Pfizer INC. | $1,081.86 | 2019-2025 | |
| Abbvie INC. | $859.04 | 2019-2025 | |
| Amgen INC. | $603.02 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Genentech USA, INC. | $536.15 | 2019-2025 | Venclexta, Polivy, Alecensa |
| Celgene Corporation | $528.25 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genzyme Corporation | $527.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $507.02 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $443.81 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $412.97 | 2020-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $400.42 | 2019-2024 | Xospata, Vyloy |
| Janssen Biotech, INC. | $396.64 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $394.93 | 2019-2025 | Imfinzi |
| Daiichi Sankyo INC. | $316.35 | 2020-2025 | Enhertu, Datroway, Injectafer |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.